An observational study in Insomnia Disorder, sponsored by Idorsia Pharmaceuticals Ltd.. Active, not recruiting at 1 site in United States. Open to female participants aged 15 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-08-19.
Sponsored by Idorsia Pharmaceuticals Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Sleep Initiation and Maintenance Disorders by Idorsia Pharmaceuticals Ltd. — none open to participants now, 1 under way, none of them phase 3. Sleep Initiation and Maintenance Disorders · Idorsia Pharmaceuticals Ltd..
Among the 11 studies in Sleep Initiation and Maintenance Disorders by Idorsia Pharmaceuticals Ltd., this one is one of 2 that started in 2023, is one of 2 observational ones, and was the 10th registered.
2,732 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 733 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →None of the 11 studies in Sleep Initiation and Maintenance Disorders by Idorsia Pharmaceuticals Ltd. is open now. The open studies under Sleep Initiation and Maintenance Disorders, anywhere →
Of the 392 Sleep Initiation and Maintenance Disorders studies recruiting now, 155 (40%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 110 take healthy volunteers.
This study: 15 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 2,095 is above the median of 138 across 319 observational studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 166 across the 9 interventional studies, 1,049 across the 2 observational. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Sleep Initiation and Maintenance Disorders by Idorsia Pharmaceuticals Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
Healthcare claims database study to provide safety information on maternal, fetal and infant outcomes among women exposed to QUVIVIQ (daridorexant) during pregnancy
This is a longitudinal observational cohort study using an electronic database of healthcare claims data. Safety information will be retrospectively collected from the database and pre-specified diagnostic codes will be used to identify pregnancy and infant outcomes. The study will include two phases, a patient accrual phase (Phase 1) and an analysis phase (Phase 2).
Descriptive statistics will be conducted to characterize the patient population and to support the interpretation of comparative analyses. Comparative analyses will be performed to estimate the effect of QUVIVIQ exposure during pregnancy on the study outcomes. Approximately 419 mother-infant pairs with exposure to QUVIVIQ and 1676 mother-infant pairs with exposure to non-orexin receptor antagonist insomnia medication are expected with a 1:4 ratio of exposed:active comparator patients.
Analysis of the prevalence of each specific pregnancy or infant outcome will comprise: (1) a comparison between women with insomnia exposed to QUVIVIQ during or shortly prior to pregnancy (QUVIVIQ-exposed group) and women with insomnia exposed to any non-orexin receptor antagonist insomnia medication during or shortly prior to pregnancy (active comparator group); (2) a comparison between women with insomnia exposed to QUVIVIQ during or shortly prior to pregnancy (QUVIVIQ-exposed group) and women with insomnia unexposed to any insomnia medication during or shortly prior to pregnancy (unexposed comparator group).
Women with an end of pregnancy event between 1 May 2022 and 31 May 2027 (called the "intake period") and a diagnosis of insomnia disorder are included in the base cohort, from which the exposure- and outcome-specific analytic cohorts will be created.
Pregnant women with insomnia exposed to QUVIVIQ during pregnancy or within 5 half-lives prior to date of conception.
Drug: Daridorexant
Pregnant women with insomnia exposed to non-orexin receptor antagonist insomnia medications during pregnancy or within 5 half-lives of the respective insomnia medication prior to date of conception.
Drug: Non-orexin receptor antagonist insomnia medication
Pregnant women with insomnia unexposed to insomnia medications during pregnancy and within 5 half-lives of any insomnia medication taken prior to date of conception.
Other: No insomnia medication
Daridorexant received during or shortly prior to pregnancy.
Also known as: QUVIVIQ
Non-orexin receptor antagonist insomnia medication received during or shortly prior to pregnancy.
No insomnia medication received during or shortly prior to pregnancy.
Prevalence of major congenital malformations (MCMs)
MCMs will be identified as pre-specified diagnostic codes for malformations included in the National Birth Defects Prevention Network's birth defects descriptions (identified through maternal and infant claims). MCMs with etiologies presumed not to be associated with drug exposure, such as chromosomal abnormalities, genetic syndromes, prematurity-related defects, and positional effects, will be excluded from the definition of MCMs.
Time frame: From May 2022 to April 2028 (6 years)
Prevalence of spontaneous abortions (SABs)
An SAB is defined as the loss of an embryo before 20 gestational weeks (identified through maternal claims).
Time frame: From May 2022 to April 2028 (6 years)
Prevalence of stillbirths (SBs)
An SB is defined as the loss of a fetus at or after 20 gestational weeks (identified through maternal claims).
Time frame: From May 2022 to April 2028 (6 years)
Prevalence of small for gestational age infants (SGAs)
SGA is defined as birth weight less than or equal to the tenth percentile for gestational age (identified through maternal and infant claims).
Time frame: From May 2022 to April 2028 (6 years)
Prevalence of preterm births (PTBs)
PTB is defined as a live birth before 37 gestational weeks (identified through maternal and infant claims).
Time frame: From May 2022 to April 2028 (6 years)
Prevalence of induced abortions (IABs)
An IAB is defined as the elective termination of the pregnancy (identified through maternal claims).
Time frame: From May 2022 to April 2028 (6 years)
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2023 (actual). Primary completion is estimated for Apr 2028, 53 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sleep Initiation and Maintenance Disorders →
Idorsia Pharmaceuticals Ltd. →